entertainment -WSS

entertainment

author：entertainment 2025-10-03 00:03:57 - browse：4837

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

WSS

Roche drug slashes death risk in early

STAT Summit: How researchers deal with rejection

Roche acquires Telavant from Roivant, adding experimental IBD treatment

How I ended up pumping milk in a bathroom stall at JPM 2024

How AI can help patients find reliable information about doctors

Why a market frenzy over new weight loss drugs defies logic

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Jerome Adams on the need for new antivirals for Covid

New menopause drug shows promise in relief for hot flashes

In age of alternative facts, a scholarly course on calling out crap

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Drug repurposing or repositioning? The language matters

Questions loom on AstraZeneca cancer drug as safety concerns ebb

The high cost of giving birth even with insurance

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Moonlake's readout produced a cash windfall. Risks remain

Fauci’s Covid grilling leads GOP to weigh foreign research rules

hotspot

Study on Amgen’s bispecific immunotherapy produces positive data

Risky weight loss products often used by teens globally, per study

UnitedHealth, Optum discontinue NaviHealth name

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

As JPM 2024 winds down, some health tech firms project optimism

Health tech investors get more selective as pandemic boom fades

leisure time

leisure time

hotspot

knowledge